Table 1.
Baseline characteristics
| Continue methotrexate (n=127) | Suspend methotrexate (n=127) | ||
|---|---|---|---|
| Age, years | 59·2 (11·0) | 59·0 (11·9) | |
| <40 years | 8 (6%) | 8 (6%) | |
| 40–64 years | 73 (57%) | 73 (57%) | |
| ≥65 years | 46 (36%) | 46 (36%) | |
| Sex | |||
| Male | 47 (37%) | 52 (41%) | |
| Female | 80 (63%) | 75 (59%) | |
| BMI, kg/m2 | 29·0 (6·5) | 30·3 (5·6) | |
| Ethnicity | |||
| White | 120 (94%) | 118 (93%) | |
| Other | 7 (6%) | 8 (6%) | |
| Missing data | 0 | 1 (1%) | |
| Smoking status | |||
| Never smoked | 67 (53%) | 68 (54%) | |
| Ex-smoker | 46 (36%) | 49 (39%) | |
| Current smoker | 14 (11%) | 10 (8%) | |
| Serum creatinine concentration, μmol/L | 71·7 (14·8) | 75·8 (13·2) | |
| Type of immune-mediated inflammatory disease | |||
| Rheumatic disease (with or without skin disease) | 101 (80%) | 102 (80%) | |
| Skin disease alone | 26 (20%) | 25 (20%) | |
| Immune-mediated inflammatory disease* | |||
| Rheumatoid arthritis | 68 (54%) | 62 (49%) | |
| Psoriasis with arthritis | 24 (19%) | 28 (22%) | |
| Psoriasis without arthritis | 15 (12%) | 19 (15%) | |
| Seronegative (axial) spondyloarthritis | 3 (2%) | 1 (1%) | |
| Reactive arthritis | 0 | 0 | |
| Atopic eczema | 6 (5%) | 6 (5%) | |
| Polymyalgia rheumatica | 2 (2%) | 3 (2%) | |
| Systemic lupus erythematosus | 2 (2%) | 0 | |
| Other rheumatic disease | 6 (5%) | 9 (7%) | |
| Other skin disease | 6 (5%) | 3 (2%) | |
| Methotrexate use | |||
| Weekly dose ≤5 mg | 55 (43%) | 51 (40%) | |
| Weekly dose >15 mg | 72 (57%) | 76 (60%) | |
| Median dose | 20 (15–20) | 20 (15–20) | |
| Oral administration | 79 (62%) | 75 (59%) | |
| Subcutaneous administration | 48 (38%) | 52 (41%) | |
| Folic acid supplementation | |||
| Yes | 124 (98%) | 125 (98%) | |
| No | 2 (2%) | 2 (2%) | |
| Missing data | 1 (1%) | 0 | |
| Hydroxychloroquine | |||
| Yes | 21 (17%) | 26 (20%) | |
| No | 106 (83%) | 101 (80%) | |
| Median dose | 200 (200–200) | 200 (200–400) | |
| Concomitant systemic medications* | |||
| Non-steroidal anti-inflammatory drugs | 22 (17%) | 23 (18%) | |
| Oral glucocorticoid | 3 (2%) | 2 (2%) | |
| Insulin | 3 (2%) | 1 (1%) | |
| Missing data | 1 (1%) | 0 | |
| Parenteral glucocorticoid in past 3 months | |||
| Intra-articular glucocorticoid | 0 | 2 (2%) | |
| Intramuscular glucocorticoid | 1 (1%) | 3 (2%) | |
| None | 125 (98%) | 122 (96%) | |
| Missing data | 1 (1%) | 0 | |
| Current use of topical glucocorticoid | |||
| Yes | 17 (13%) | 20 (16%) | |
| No | 110 (87%) | 107 (84%) | |
| Comorbidities* | |||
| Diabetes | 16 (13%) | 10 (8%) | |
| Hypertension | 30 (24%) | 28 (22%) | |
| Ischaemic heart disease | 1 (1%) | 3 (2%) | |
| Congestive cardiac failure | 0 | 0 | |
| Asthma | 18 (14%) | 16 (13%) | |
| Chronic obstructive pulmonary disease | 3 (2%) | 5 (4%) | |
| High cholesterol | 12 (9%) | 16 (13%) | |
| Stroke (including transient ischaemic attack) | 2 (2%) | 3 (2%) | |
| None of the above | 71 (56%) | 77 (61%) | |
| Primary COVID-19 vaccination type | |||
| mRNA (BNT162b2 or mRNA-1273) | 42 (33%) | 43 (34%) | |
| Viral vector (AZD1222) | 85 (67%) | 82 (65%) | |
| Combination | 0 | 2 (2%) | |
| Days between two doses | 76 (11·0) | 76 (12·0) | |
| COVID-19 disease history | |||
| COVID-19 disease leading to hospitalisation | 1 (1%) | 3 (2%) | |
| COVID-19 disease without hospitalisation | 16 (13%) | 21 (17%) | |
| No COVID-19 disease | 110 (87%) | 103 (81%) | |
| COVID-19 booster vaccine | |||
| BNT162b2 | 106 (83%) | 102 (80%) | |
| AZD1222 | 6 (5%) | 4 (3%) | |
| mRNA-1273 | 13 (10%) | 18 (14%) | |
| None | 2 (2%) | 3 (2%) | |
| Booster as 3rd dose† | 124 (99%) | 124 (100%) | |
| Booster as 4th dose† | 1 (1%) | 0 | |
| Days between previous vaccination and booster | 189·9 (31·0) | 195·4 (22·1) | |
Data are n (%), mean (SD), or median (IQR).
*
Participants can have more than one category.
†
Percentages are of those who received a booster vaccine.